ASCO 2025

De-escalating therapy - a step forward

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

Intraoperative dose escalation helps to reach targeted…

HRD and BRCA status as a new innovative staging system?

WSG: HER2+ pooled analysis

A new standard for endocrine-resistant HR+ MBC?

SG + Pembro in aTNBC: a new standard of care?

New compounds - new approaches: TNBC | HR+ | HER2+

A new standard for the firstline treatment of HER2+…

SERENA-6 - a challenging strategy?

Next-gen endocrine therapies and ADCs: Updates from…

AI and ADCs: Precision diagnostics & safer rechallenge…

Re-exposition and ILD

New treatment option in first line of metastatic TNBC

ASCENT-04

ABC for metastatic TNBC

New SOC in first-line treatment for primary endocrine…

Liquid biopsy as a navigator for personalized therapy…

Sac-TMT for metastatic TNBC

New firstline SOC for HER2+ metastatic BC

A new first-line therapy for TNBC

Additional chemo-free option for TNBC

Vepdegestrant for treatment of ER+/HER2- aBC

T-DXd: Detecting ILD and treat again

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

New AKT/PIK3 Antagonist for treatment of mBC after…

Final OS-Analysis of INAVO-120 trial

SG + Pembrolizumab might become SOC for PD-L1-positive…

Effective ADC for HER2+ mBC with brain metastases

Additional ADC effective for untreated TNBC

Un nouveau traitement de première ligne pour le TNBC

Vepdegestrant per il trattamento di ER+/HER2- aBC

Una nuova terapia di prima linea per il TNBC

Nuova opzione di trattamento in prima linea per il TNBC…

Analisi finale della OS dello studio INAVO-120

SG + Pembrolizumab podría convertirse en el tratamiento…

Nuovo antagonista di AKT/PIK3 per il trattamento della…

A bright future? Radioligands, hormonal treatment…

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

Localized CSPC - innovations

MMAI Model identifies patients who benfit from ARPI in…

mHSPC - ADT + NHT updates

Rebirth of Rucaparib

Real world data from ironman registry confirms…

mHSPC - prognostification - indications on integration?

Stereotactic beam radiation therapy 2.0

Adding EZH2 to Enzalutamide to decrease the development…

CAN-2409 Offers First New Option in 20 Years

News of ANZUP trial

Niraparib + Abiraterone Improves Outcomes in…

Immuntherapy - an evolution?

Combination of LU-PSMA and immunotherapy, EVOLUTION…

New way of treatment for PCa

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

ICI Combos in 1L and Maintenance – Mixed Bags or…

Sasanlimab + BCG: Practice-Changing Potential for…

ctDNA Clearance Confirms Added Value of Perioperative…

Response matters in advanced urothelial cancer patients…

Intensive caution of BCG Therapy

The role of sansalimab (+ SG) in BCG-naive and…

New option for high-risk NMIBC

Update on EV-PEM in the EV-302 study

New nectin-4 ADCs are coming

mUC - new approaches?

CREST Study: Promising Results with PD-1 Inhibitor…

NIAGARA study and circulating tumor DNA

A new prognostic factor in bladder cancer?: The case of…

mUC EVP + subsequent therapies

ASCO 2025 - Highlights for Bladder Cancer

Benefit of IO/IO therapy in mUC

ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου…

De nouveaux ADC pour la nectine-4 arrivent

El rol de sansalimab (+ SG) en el carcinoma urotelial…

¿Un nuevo factor pronóstico en el cáncer de vejiga? El…

HIF alfa sigue siendo una diana interesante en el RCC y…

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

Who Really Benefits? Pembro’s Solid, Atezo’s Still…

PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions

First lession

5-Year OS data from the KEYNOTE-564 study

Nivo + Ipi - Update & Insights

HIF alpha still an interesting target in RCC and other…

Long-term outcome of Nnivo-Ipi in clear cell RCC

Allogeneic CD70 CAR T Cells in refractory RCC

New synergies? Radiotherapy and IO in Limited-Stage…

cTDNA in periop chemo-IO strategies

Neoadjuvant Alectinib in resectable stage III NSCLC

Chemoimmunotherapy followed by chemoradiotherapy

Updates in perioperative strategies in NSCLC

CheckMate 816: Update on OS-benefit

CM-816: The OS results are positive and demonstrate…

Neadjuvant targeted therapy

ctDNA stratification

Actualizaciones en estrategias perioperatorias en NSCLC

CheckMate 816 : Mise à jour sur les avantages du…

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

HERTHENA-Lung02 unfortunately negative study -…

Immunotherapy – before or after 3 p.m.?

TROP2 targets – where is first-line development…

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

Time of day of immunotherapy is important

Is there still a place for HER3-DXd in advanced NSCLC?

Updates on ADCs in EGFR resistance

Have we MET our target?

RELA-104-biomarker-analysis

Does the timing of IO-infusion impact survival?

ADC as 3L in EGFR

KRAS G12C: Can immunotherapy improve patient outcome…

HER3-DXd: dissapointing negative trial

Sevarbertinib – an additional option for HER2 exon 20…

ADC in the 3L beats docetaxel

Actualizaciones sobre los ADC en la resistencia al EGFR

Hebben we ons doel gehaald?

HERTHENA-Lung02 étude malheureusement négative -…

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

New maintenance therapy for SCLC

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

The first positive maintenance therapy in SCLC

Taralatamb - the new SOC in 2L treatment

Tarlatamab - a new SOC in second line

DeLLphi-304 : Changement radical dans le traitement de…

LA HNSCC - New neoadjuvant SOC